Table 1.
Factor | No. of Patients | %b | % of Person-Time Retainedc |
Agreement Between RLB and REB |
||
---|---|---|---|---|---|---|
REB | RLB | κ | % | |||
Total | 83,041 | 100 | 71 | 67 | 0.59 | 80 |
Age, years | ||||||
<40 | 35,713 | 43 | 62 | 63 | 0.64 | 83 |
40–49 | 29,542 | 36 | 70 | 67 | 0.61 | 83 |
50–59 | 13,863 | 17 | 77 | 68 | 0.53 | 81 |
≥60 | 3,923 | 5 | 84 | 70 | 0.39 | 78 |
Sex | ||||||
Male | 67,951 | 82 | 71 | 66 | 0.57 | 80 |
Female | 15,090 | 18 | 69 | 69 | 0.57 | 80 |
Race/ethnicity | ||||||
Non-Hispanic white | 33,207 | 40 | 72 | 69 | 0.56 | 82 |
Non-Hispanic black | 34,175 | 41 | 69 | 62 | 0.60 | 82 |
Hispanic | 9,510 | 11 | 72 | 73 | 0.64 | 86 |
Other/unknown | 6,149 | 7 | 70 | 67 | 0.59 | 82 |
Primary HIV risk factor | ||||||
Men who have sex with men | 30,589 | 37 | 69 | 74 | 0.63 | 85 |
Injection drug user | 14,329 | 17 | 69 | 58 | 0.58 | 80 |
Heterosexual contact | 18,908 | 23 | 68 | 71 | 0.65 | 85 |
Other/unknown | 19,215 | 23 | 76 | 59 | 0.49 | 77 |
CD4-positive T-lymphocyte count, cells/mm3 d | ||||||
<200 | 19,322 | 29 | 70 | 69 | 0.64 | 85 |
200–349 | 14,718 | 22 | 73 | 74 | 0.63 | 86 |
350–499 | 12,940 | 20 | 74 | 75 | 0.61 | 85 |
≥500 | 19,061 | 29 | 75 | 76 | 0.59 | 85 |
HIV-1 RNA level, copies/mLd | ||||||
<200 | 16,972 | 27 | 81 | 83 | 0.52 | 86 |
≥200 | 45,205 | 73 | 69 | 68 | 0.63 | 84 |
Receipt of ART for ≥6 months/yeare | ||||||
No ART | 46,449 | 56 | 50 | 42 | 0.57 | 79 |
ART | 36,592 | 44 | 83 | 82 | 0.46 | 84 |
Country of care | ||||||
United States | 79,236 | 95 | 70 | 66 | 0.58 | 82 |
Canada | 3,805 | 5 | 74 | 75 | 0.66 | 87 |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; HIV-1, HIV type 1; NA-ACCORD, North American AIDS Cohort Collaboration on Research and Design.
a Encounter-based retention (REB) was defined as ≥2 primary care encounters in a calendar year, ≥90 days apart. Laboratory-based retention (RLB) was defined similarly, using the dates of CD4-positive cell counts or HIV-1 RNA measurements.
b Percentages may not sum to 100 because of rounding.
c The percentage of person-time retained in care during the study according to the encounter-based measure (REB) (i.e., the percentage of years spent “in care” between cohort entry and the final encounter) differed from the percentage of person-time retained according to the laboratory-based measure (RLB) within every stratum (χ2 test: P < 0.01).
d Data on CD4-positive cell count (n = 66,041) and HIV-1 RNA level (n = 62,177) at cohort entry were not available for all participants.
e Receipt of ART (≥3 agents from ≥2 classes or a triple nucleoside/nucleotide reverse transcriptase inhibitor regimen containing abacavir or tenofovir) during the year of cohort entry.